共 67 条
[1]
Kindler HL(2001)Metastatic colorectal cancer Curr Treat Options Oncol 2 459-471
[2]
Shulman KL(2016)ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Ann Oncol 27 1386-1422
[3]
Van Cutsem E(2007)Panitumumab the first fully human monoclonal antibody: from the bench to the clinic Anticancer Drugs 18 7-15
[4]
Cervantes A(2012)Panitumumab: a summary of clinical development in colorectal cancer and future directions Future Oncol 8 373-389
[5]
Adam R(2009)Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy Cancer 115 1544-1554
[6]
Cohenuram M(2008)Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626-1634
[7]
Saif MW(2010)Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 4697-4705
[8]
Argiles G(2010)Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 4706-4713
[9]
Dienstmann R(2011)An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer Clin Colorectal Cancer 10 171-177
[10]
Elez E(2011)The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (skin toxicity evaluation protocol with panitumumab) by KRAS status Clin Colorectal Cancer 10 333-339